Novo Nordisk ® ema in REDEFINE 1 icipants achieve BMI < 27 pants with a Waist-to- 0.53 at week 68 Proportion of participants with BMI <27 kg/m 2 and WHtR <0.53 at week 68 50 Participants in group (%) +31%-p 40 30 29.4 +28%-p 2.1 11.5 5.0 mg cagrilintide 2.4 mg 20 10 0 Placebo 16.4 8.2 1.9 semaglutide 2.4 mg; BMI and WHtR indicators of achieving a low 10-year ORC risk, Busetto, Obes Facts 2024;17(suppl 1):7 –
Download PDF file